AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17553051 — intervention group
Group type: COMPARATOR
Intervention: Terbinafine alone once daily for 3 months (T group)
Number of subjects: 249
Study 15637528 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol with D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) (0.04%)
Number of subjects: 9
Study 15637528 — intervention group
Group type: COMPARATOR
Intervention: Talinolol with Poloxamer 188 (0.8%)
Number of subjects: 9
Study 12117037 — intervention group
Group type: EXPERIMENTAL
Intervention: Airmax inhaler at fast flow rate (60 l min(‐1))
Number of subjects: 12
Study 12117037 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler at fast flow rate (60 l min(‐1))
Number of subjects: 12
Study 12117037 — intervention group
Group type: EXPERIMENTAL
Intervention: Airmax inhaler at slow flow rate (30 l min(‐1))
Number of subjects: 12
Study 12117037 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler at slow flow rate (30 l min(‐1))
Number of subjects: 12
Study 12117037 — intervention group
Group type: COMPARATOR
Intervention: pMDI at slow flow rate (30 l min(‐1))
Number of subjects: 12
Study 10662396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 240
Study 10662396 — intervention group
Group type: COMPARATOR
Intervention: Usual antibacterial care
Number of subjects: 240
Study 7487784 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric case management using an assertive community treatment model involving general practitioners
Number of subjects: 59
Study 7487784 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient care
Number of subjects: 59
Study 7487784 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric case management
Number of subjects: 59
Study 2151518 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (DMP; 20 mg orally)
Number of subjects: 7
Study 2151518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7422533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pentaerythritol tetranitrate
Number of subjects: 0
Study 7422533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pentaerythritol tetranitrate (high dosage)
Number of subjects: 0
Study 7422533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31667917 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (600, 2000, and 4000 IU d-1 for 16 weeks)
Number of subjects: 64
Study 31667917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 31127705 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular amniotic membrane seeded with Wharton's jelly mesenchymal stem cells (WJSCs) for 9 days, every 3 days
Number of subjects: 5
Study 28322505 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (10% CP/PF) (Opalescence PF)
Number of subjects: 92
Study 28322505 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide (6% HP/Go) (Opalescence Go)
Number of subjects: 92
Study 28322505 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 92
Study 25562379 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-IV criteria for acute stress disorder (ASD)
Number of subjects: 596
Study 25562379 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-5 criteria for acute stress disorder (ASD)
Number of subjects: 596
Study 25562379 — intervention group
Group type: COMPARATOR
Intervention: Comparison of DSM-IV and DSM-5 ASD definitions
Number of subjects: 596
Study 25562379 — intervention group
Group type: COMPARATOR
Intervention: Sensitivity for psychiatric disorders
Number of subjects: 596
Study 22823069 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Internet program (EI; N = 25)
Number of subjects: 53
Study 22823069 — intervention group
Group type: COMPARATOR
Intervention: Standard Internet program (SI; N = 28)
Number of subjects: 53
Study 21297567 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (300 mg . kg . day ‐1)
Number of subjects: 7
Study 21297567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 7
Study 19444412 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of a central venous catheter in patients with coagulopathy
Number of subjects: 196
Study 16720746 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported depressive symptoms and vitality scores
Number of subjects: 266
Study 16720746 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change
Number of subjects: 266
Study 16720746 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitality and depressive symptoms
Number of subjects: 266
Study 16720746 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 266
Study 11828226 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking at an intensity of 65-75% VO(2peak)
Number of subjects: 18
Study 11828226 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise
Number of subjects: 18
Study 11828226 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest
Number of subjects: 18
Study 10406241 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA/PC (Aspirin associated with phosphatidylcholine)
Number of subjects: 16
Study 10406241 — intervention group
Group type: COMPARATOR
Intervention: ASA (Aspirin alone)
Number of subjects: 16
Study 10406241 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA
Number of subjects: 16
Study 10406241 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA/PC
Number of subjects: 16
Study 7590638 — intervention group
Group type: COMPARATOR
Intervention: Low protein‐high fat evening meal (5% protein, 60% fat, 35% carbohydrate)
Number of subjects: 8
Study 7590638 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein‐low fat evening meal (35% protein, 30% fat, 35% carbohydrate)
Number of subjects: 8
Study 7590638 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 8
Study 2119897 — intervention group
Group type: EXPERIMENTAL
Intervention: (NANP)3-TT
Number of subjects: 123
Study 2119897 — intervention group
Group type: COMPARATOR
Intervention: TT alone (Control)
Number of subjects: 123
Study 7228446 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 10
Study 7228446 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 10
Study 31777299 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable colistin plus nebulized colistin
Number of subjects: 60
Study 31777299 — intervention group
Group type: COMPARATOR
Intervention: Injectable colistin plus nebulized tobramycin
Number of subjects: 60
Study 28355973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 85
Study 28355973 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT integrated with motivational interviewing
Number of subjects: 85
Study 28355973 — intervention group
Group type: COMPARATOR
Intervention: Low initial patient-rated alliance and low convergence
Number of subjects: 85
Study 28351376 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke user‐tested patient information sheet (PIS)
Number of subjects: 6900
Study 28351376 — intervention group
Group type: EXPERIMENTAL
Intervention: Template‐developed patient information sheet (PIS)
Number of subjects: 6900
Study 28351376 — intervention group
Group type: COMPARATOR
Intervention: Control patient information sheet (PIS)
Number of subjects: 6900
Study 26022813 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib (a cholesteryl ester transfer protein inhibitor)
Number of subjects: 16818
Study 26022813 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 16818
Study 24016503 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB)
Number of subjects: 208
Study 24016503 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (BA)
Number of subjects: 208
Study 21173357 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous quality improvement interventions
Number of subjects: 361328
Study 21173357 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 361328
Study 19065845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal masks with exhaust vents (EV)
Number of subjects: 5
Study 19065845 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial masks with exhaust vents (EV)
Number of subjects: 5
Study 19065845 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacers attached to nasal hermetic masks
Number of subjects: 5
Study 16373526 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy consent for incapacitated adults
Number of subjects: 2445
Study 12602423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)
Number of subjects: 75
Study 12602423 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion group (DG)
Number of subjects: 75
Study 12602423 — intervention group
Group type: COMPARATOR
Intervention: Waiting period
Number of subjects: 75
Study 10430816 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antihyperglycemic agents
Number of subjects: 0
Study 7558380 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate, 200 mg IM, weekly injections during the suppression (6‐month) and efficacy (12‐month) phases.
Number of subjects: 670
Study 2331243 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training in temporal artery constriction during headaches
Number of subjects: 23
Study 2331243 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training in temporal artery constriction during stress periods
Number of subjects: 23
Study 2331243 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training to dilate the temporal arteries during stress periods
Number of subjects: 23
Study 496621 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000‐IU vitamin E capsules (alpha‐tocopherol) administered daily for 28 days
Number of subjects: 35
Study 496621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 496621 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000‐IU vitamin E capsules (alpha‐tocopherol)
Number of subjects: 35
Study 31787421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 163
Study 31787421 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 163
Study 30650245 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based mindfulness-based cognitive therapy (MBCT)
Number of subjects: 84
Study 30650245 — intervention group
Group type: COMPARATOR
Intervention: Therapist competence
Number of subjects: 84
Study 30650245 — intervention group
Group type: COMPARATOR
Intervention: Group cohesion
Number of subjects: 84
Study 28574379 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for DFS
Number of subjects: 97
Study 28574379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin 10 ml 0.9% NaCl 200 ml for 10 days, followed by 2 tablets 2 times per day orally for one month
Number of subjects: 97
Study 27789061 — intervention group
Group type: EXPERIMENTAL
Intervention: Support intervention (referral to a weight management group, 12 sessions of 1 hour each, once per week)
Number of subjects: 1882
Study 27789061 — intervention group
Group type: COMPARATOR
Intervention: Advice intervention (advised that health would benefit from weight loss)
Number of subjects: 1882
Study 27789061 — intervention group
Group type: EXPERIMENTAL
Intervention: Support intervention
Number of subjects: 1882
Study 27789061 — intervention group
Group type: COMPARATOR
Intervention: Advice intervention
Number of subjects: 1882
Study 27789061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1882
Study 25029675 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-ingredient supplement enriched with l-glutamine and l-carnitine-l-tartrate
Number of subjects: 10
Study 25029675 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate supplement
Number of subjects: 10
Study 25029675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 25029675 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-ingredient supplement
Number of subjects: 10
Study 22278200 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange transfusion therapy
Number of subjects: 6
Study 19056578 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (30 g)
Number of subjects: 24
Study 19056578 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose (75 g)
Number of subjects: 24
Study 17242107 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating catheter (SC group)
Number of subjects: 40
Study 17242107 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter (CC group)
Number of subjects: 40
Study 15710594 — intervention group
Group type: EXPERIMENTAL
Intervention: Morel's prognostic scoring system
Number of subjects: 92
Study 12475466 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (0.01 mg/kg/day titrated up to 0.2 mg/kg/day)
Number of subjects: 22
Study 12475466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9535429 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg aspirin daily
Number of subjects: 926
Study 9535429 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg daily
Number of subjects: 926
Study 9535429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 926
Study 7608438 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (9 g/day intravenously for the first 5 days, then 6 g/day orally for 12 months)
Number of subjects: 472
Study 7608438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study 7608438 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 472
Study 29436337 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin for 42 days
Number of subjects: 186
Study 29436337 — intervention group
Group type: COMPARATOR
Intervention: Standard care without rifaximin
Number of subjects: 186
Study 27330709 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + PDT (with diode laser 808 nm, 0.5 W)
Number of subjects: 18
Study 27330709 — intervention group
Group type: COMPARATOR
Intervention: SRP (scaling and root planning)
Number of subjects: 18
Study 27330709 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser + SRP (with diode laser 808 nm, 1 W)
Number of subjects: 18
Study 27330709 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (810n m wavelength, 1.5 W and 320 μm fiber)
Number of subjects: 18
Study 26241700 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP24A1 rs927650 T allele
Number of subjects: 1188
Study 26241700 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP24A1 rs35051736
Number of subjects: 1188
Study 26241700 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP24A1 rs2296241
Number of subjects: 1188
Study 26241700 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP24A1 rs2762939
Number of subjects: 1188
Study 23958241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone, 45 mg/d for 6 months
Number of subjects: 20
Study 23958241 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin, 2 g/day added after pioglitazone
Number of subjects: 20
Study 23958241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21168835 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic trimodal imaging (ETMI)
Number of subjects: 99
Study 21168835 — intervention group
Group type: COMPARATOR
Intervention: Standard video endoscopy (SVE)
Number of subjects: 99
Study 19046778 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilingual education (spoken + sign language)
Number of subjects: 18
Study 19046778 — intervention group
Group type: COMPARATOR
Intervention: Spoken language education
Number of subjects: 18
Study 19046778 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bilingual and spoken language)
Number of subjects: 18
Study 16962109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer
Number of subjects: 730
Study 16962109 — intervention group
Group type: COMPARATOR
Intervention: Embryo transfer based on previous ultrasonographic length measurement
Number of subjects: 730
Study 15236870 — intervention group
Group type: EXPERIMENTAL
Intervention: 5x5Gy short-term irradiation
Number of subjects: 316
Study 15236870 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation to a total dose of 50.4Gy (1.8Gy per fraction) with two courses of bolus 5-fluorouracil and leucovorin
Number of subjects: 316
Study 15236870 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 316
Study 11736860 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg diazepam i.n.
Number of subjects: 8
Study 11736860 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg diazepam i.n.
Number of subjects: 8
Study 11736860 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intravenous diazepam
Number of subjects: 8
Study 11736860 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 8
Study 9431617 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrel‐Dubousset instrumentation
Number of subjects: 130
Study 9431617 — intervention group
Group type: COMPARATOR
Intervention: No instrumentation
Number of subjects: 130
Study 8214649 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1-2 mg/kg for induction and sufentanil 0.03 micrograms.kg-1.min-1 plus propofol 50-200 micrograms.kg-1.min-1 for maintenance (Group A)
Number of subjects: 60
Study 8214649 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 5 micrograms/kg for induction and propofol 50-200 micrograms.kg-1.min-1 for maintenance (Group B)
Number of subjects: 60
Study 8214649 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 5 micrograms/kg for induction and enflurane for maintenance (Group C)
Number of subjects: 60
Study 3697322 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE-mediated, food-induced asthma
Number of subjects: 0
Study 3697322 — intervention group
Group type: EXPERIMENTAL
Intervention: Food allergy respiratory symptoms
Number of subjects: 0
Study 3697322 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated case of cough due to food allergy
Number of subjects: 0
Study 31667678 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of ring use to male partners
Number of subjects: 2629
Study 31667678 — intervention group
Group type: EXPERIMENTAL
Intervention: Male partner attendance at the study clinic
Number of subjects: 2629
Study 31667678 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive male partner
Number of subjects: 2629
Study 31667678 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupportive male partner
Number of subjects: 2629
Study 31667678 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of ring use
Number of subjects: 2629
Study 31667678 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner attendance at the clinic
Number of subjects: 2629
Study 29482042 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS applied to the left dorsolateral prefrontal cortex
Number of subjects: 0
Study 29482042 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 0
Study 29482042 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 0
Study 27273192 — intervention group
Group type: EXPERIMENTAL
Intervention: 1997 mothers (high-risk pregnancy)
Number of subjects: 120
Study 27273192 — intervention group
Group type: EXPERIMENTAL
Intervention: 2015 mothers (first-time mothers)
Number of subjects: 120
Study 27273192 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 120
Study 24520910 — intervention group
Group type: EXPERIMENTAL
Intervention: DeREACH (intervention consisting of nine home visits and three telephone contacts over six months)
Number of subjects: 138
Study 24520910 — intervention group
Group type: EXPERIMENTAL
Intervention: DeREACH (intervention)
Number of subjects: 138
Study 22661750 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (6 ml kg(‐1) predicted body weight)
Number of subjects: 101
Study 22661750 — intervention group
Group type: COMPARATOR
Intervention: High tidal volume ventilation (12 ml kg(‐1) predicted body weight)
Number of subjects: 101
Study 20200338 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ibudilast
Number of subjects: 297
Study 20200338 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg ibudilast
Number of subjects: 297
Study 20200338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 20200338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (both doses)
Number of subjects: 297
Study 18155854 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive musical mood induction procedures (MMIP) for EM drinkers
Number of subjects: 160
Study 18155854 — intervention group
Group type: COMPARATOR
Intervention: Negative musical mood induction procedures (MMIP)
Number of subjects: 160
Study 15986348 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 180
Study 12919884 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) at 0.12 mJ/mm(2)
Number of subjects: 88
Study 12919884 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 88
Study 12919884 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 88
Study 10329871 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered misoprostol (50 micrograms every 4 hours)
Number of subjects: 220
Study 10329871 — intervention group
Group type: COMPARATOR
Intervention: Vaginally administered misoprostol (25 micrograms every 4 hours)
Number of subjects: 220
Study 10329871 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered misoprostol
Number of subjects: 220
Study 10329871 — intervention group
Group type: COMPARATOR
Intervention: Vaginally administered misoprostol
Number of subjects: 220
Study 10329871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 220
Study 7562150 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression hip screw
Number of subjects: 90
Study 7562150 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandeputte (VDP) endoprosthesis
Number of subjects: 90
Study 2007107 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg hyperbaric bupivacaine
Number of subjects: 27